Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.72 |
| ▸ | ITGAV | P06756 | 18/20 | 0.72 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.72 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.72 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.72 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833670 | 0.92 | ITGB3 (0.67) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL6419266 | 0.84 | ITGB3 (0.73) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7168382 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL244383 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL6657173 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL30894723 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL31321064 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL328727 | 0.81 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL6419346 | 0.81 | ITGB3 (0.82) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7076039 | 0.80 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058915-A1 | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-25 | — | — | US | claimed |
| EP-1320530-A1 | COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS | Pharmacia Corporation (US) | 2003-06-25 | — | — | EP | claimed |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | claimed |
| WO-2002018377-A1 | COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |
| US-20040058915-A1 | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists | PHARMACIA CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1320530-A1 | COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS | Pharmacia Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | disclosed |
| WO-2002018377-A1 | COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | ITGB1, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 9/4885ITGB1 1/4885 |
| US-20040058915-A1 | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists | ITGB5, ITGB3, ITGAV | ITGB3 2/4885ITGAV 3/4885ITGB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.